Suivis de recherche
Toutes les questions ouvertes soulevées au fil des 18 interviews, regroupées par interview. La plupart sont des tâches de sourçage — localiser un document, une page ou une citation. Chaque suivi indique les documents que Christine Cotton cite dans son livre, avec des liens (et des copies archivées lorsque l'original a été déplacé). Cochez les éléments au fur et à mesure — votre progression est enregistrée dans votre navigateur.
72 suivis de recherche à travers 18 interviews
Le désastre sanitaire ne fait que commencer I Christine Cotton
-
Cotton states this twice for emphasis at ~02:00 of the Cercle Aristote interview. The flagship FOIA-able citation.Sources qu'elle cite dans le livre
- 30 FDA — William Gruber (Pfizer) VRBPAC presentation slides for BNT162b2, FDA meeting of 10 December 2020 (efficacy results by age group)
- 32 VIDAL (vidal.fr) — COMIRNATY vaccine page, February 2021 (Wayback Machine archive, captured 25 Feb 2021)
- 192 French National Assembly / OPECST — information report 'The Covid-19 Vaccine Strategy' (l15b3695), 15 December 2020
-
Cited at ~08:47 as proof that contracts were signed on impossible claims about trial completion.
-
Cited at ~19:30 — the smoking gun for the vaccine-vs-gene-therapy reclassification argument.Sources qu'elle cite dans le livre
-
Cited at ~19:30 as proof harms were anticipated before rollout.Sources qu'elle cite dans le livre
- 91 FDA YouTube channel — video recording of the VRBPAC public meeting broadcast live 22 October 2020
- 92 FDA — full transcript of the VRBPAC meeting of 22 October 2020
- 93 FDA — Tom Shimabukuro (CDC) presentation slides, VRBPAC meeting 22 October 2020 (Preliminary list of VAERS AEs of special interest)
- 94 FDA — Steve Anderson (FDA CBER) presentation slides, VRBPAC meeting 22 October 2020
-
Central to the "product administered is not the product tested" argument (~11:20).Sources qu'elle cite dans le livre
- 296 NEJM — Pfizer/BioNTech C4591001 clinical study protocol (supplementary appendix to Polack et al., NEJMoa2034577, December 2020) ⧉ archivé
- 299 EMA — Comirnaty EPAR public assessment report (CHMP assessment report, 19 February 2021)
- 300 BMJ — rapid response by Joshua Guetzkow on the Pfizer manufacturing-process change (bmj.o1731) ⧉ archivé
Covid : où en sont les chiffres en 2023 ?
-
Cited at 08:19 — flagship documentary evidence that the unknowns persisted into the pediatric authorization.Sources qu'elle cite dans le livre
- 74 FDA — Pfizer-BioNTech COVID-19 Vaccine, adolescent (12-15) clinical/EUA review document (released to the public April/May 2021)
- 76 FDA — Pfizer-BioNTech COVID-19 Vaccine, adolescent (12-15) clinical/EUA review document (2021)
- 79 PHMPT — Complaint, de Garay v. FDA (filed 11 Oct 2022), hosted at phmpt.org ⧉ archivé
- 83 CCNE (French National Consultative Ethics Committee) — opinion on ethical issues of COVID-19 vaccination in children and adolescents, 8 June 2021 ⧉ archivé
-
Cotton states at 12:11 that EMA reservations are "all documented" — locating the EPAR passage gives the archive a durable citation.Sources qu'elle cite dans le livre
- 299 EMA — Comirnaty EPAR public assessment report (CHMP assessment report, 19 February 2021)
- 296 NEJM — C4591001 study protocol, supplementary appendix to Polack et al. (NEJMoa2034577), Dec 2020 ⧉ archivé
- 296 NEJM — Polack et al., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (NEJMoa2034577), Dec 2020 ⧉ archivé
- 297 EMA — press release 'Cyberattack on EMA – update 5'
- 298 EMA — press release 'Cyberattack on EMA – update 4'
- 300 The BMJ — rapid response by Joshua Guetzkow to BMJ 2022;378:o1731 ⧉ archivé
-
Cited at 17:12 as the empirical basis for Cotton's 10×–100× under-reporting multiplier.Sources qu'elle cite dans le livre
-
Bercoff reads the ANSM figures in the intro (~03:30); they frame the entire interview as the 95% / 4.25% / 45% reality check.
La vérité sur les essais Pfizer - Le Zoom - Christine Cotton - TVL
-
Cotton turns directly to page 8 at 01:22 — exhibit A for the contracts-vs-trial-completion argument.
-
Cited at 11:06 — the regulatory pivot that made the truncated follow-up legal.
-
Cited at 18:55 — a French health-establishment figure who had read the macaque publication and warned about antibody waning, then disappeared from public view.Sources qu'elle cite dans le livre
- 131 FDA briefing/review document for the Pfizer-BioNTech BNT162b2 EUA (FDA, December 2020)
- 132 Pfizer/BioNTech pre-clinical immunogenicity study in macaques, bioRxiv preprint (posted September 8, 2020) ⧉ archivé
- 133 France Info (francetvinfo.fr) article/interview, 'Vaccin contre le coronavirus: Philippe Douste-Blazy exhorte à la patience' (November 9, 2020)
-
Cited at 17:12 as the formal record of Cotton bringing her critique to French parliament and regulator.Sources qu'elle cite dans le livre
- 192 French National Assembly / OPECST rapporteurs' information report 'The Covid-19 Vaccine Strategy' (December 15, 2020)
- 200 OPECST rapporteurs' interim report on adverse effects of COVID-19 vaccines and the French pharmacovigilance system (National Assembly, published June 9, 2022)
- 237 Michèle Rivasi (michele-rivasi.eu) page — debrief with biostatistician Christine Cotton on the efficacy of the Pfizer anti-COVID vaccine (May 2022)
-
Cited at 22:38 — one of the most striking individual cases in Cotton's victim chapter.Sources qu'elle cite dans le livre
Christine Cotton : « On a des risques qui sont parfaitement documentés ! » #COVID19
-
Cotton mentions the visits in this interview at 22:43 and details them more fully in the Cercle Aristote interview — a flagship example of the institutional response to her report.
-
Cited at 28:39 — Cotton mentions OPECST as part of her whistleblower channel.Sources qu'elle cite dans le livre
- 192 French National Assembly / OPECST — information report 'The Covid-19 Vaccine Strategy' (Rapport d'information n. 3695), 15 December 2020
- 200 French National Assembly / OPECST — interim report by the rapporteurs on adverse effects of Covid-19 vaccines and the pharmacovigilance system, published 9 June 2022
- 237 Michèle Rivasi (MEP) website — debrief 'La biostatisticienne Christine Cotton sur l'efficacité du vaccin anti-COVID Pfizer', early May 2022
-
Cited at 21:00 — Cotton uses this to support her counter-attack against the fact-checking establishment.
-
Cotton makes this point at 47:36 — useful for cross-linking the Cotton archive to the broader controversy over French regulatory consistency.
Covid19 - Christine Cotton : "La science ce n'est pas de la politique, c'est de la statistique !"
-
Cited at 16:25 as the smoking-gun statistic that the 95% headline was driven by the choice of endpoint.Sources qu'elle cite dans le livre
- Pfizer C4591001 trial database / SAS dataset made publicly available by attorney Aaron Siri (ICAN/Siri & Glimstad, via court-released FDA documents)
- 150 OpenVAET (Substack) — 'Pfizer/BioNTech C4591001 Trial Audit'
- 149 WHO — Technical briefing (April 2021), 'Regulation of COVID-19 vaccines' synopsis Aug 2020–Feb 2021 ⧉ archivé
-
Critical follow-up: an unpublished pregnancy trial undermines official agency assurances that there is "no signal" in pregnant women.Sources qu'elle cite dans le livre
-
A French regulator stating publicly that the data did not support efficacy on the elderly or severe forms — a citable counterweight to the 95% messaging.Sources qu'elle cite dans le livre
- 30 FDA — VRBPAC meeting (10 Dec 2020), Pfizer/BioNTech BNT162b2 sponsor presentation by William Gruber
- 31 VIDAL (vidal.fr), archived 25 Feb 2021 via the Wayback Machine — COMIRNATY vaccine page
- 32 VIDAL (vidal.fr), archived 25 Feb 2021 via the Wayback Machine — COMIRNATY vaccine page (citation for the quoted text)
-
Both callers (~24:00 and ~26:08) ground the abstract critique in the lived experience of mandated French professionals.
« J'ai découvert la face cachée de l'industrie pharmaceutique » – Christine Cotton
-
Cited at 18:40 — a single site holding ~15% of the entire C4591001 enrolment, and the locus of the Roux fraud allegation.Sources qu'elle cite dans le livre
- 85 DavidHealy.org (Data Based Medicine) — "Disappeared in Argentina," blog post on the Augusto Roux case at the Cosme Argerich Military Hospital Pfizer trial site
- 86 VaccineHarm (WordPress), 29 December 2020 — account/documentation of Augusto German Roux's adverse events after the Pfizer trial vaccine
- 88 PubMed (NCBI/NLM) — peer-reviewed article co-authored by Roux and Brianne Dressen documenting that four doctors confirmed Roux's injuries were vaccine-induced
-
Cited at 17:49 as one of the strongest publicly available pieces of evidence for site-level GCP violations.Sources qu'elle cite dans le livre
- 152 Ventavia Research Group corporate website ⧉ archivé
- 153 The BMJ — Paul D. Thacker, "Covid-19: Researcher blows the whistle on data integrity issues in Pfizer's vaccine trial," BMJ 2021;375:n2635 (2 November 2021) ⧉ archivé
- 272 iambrookjackson.com — public case-documents repository for the False Claims Act lawsuit (U.S. ex rel. Jackson v. Ventavia/Pfizer)
-
Cited at 45:37 as the French legal vehicle for Cotton's expertise.Sources qu'elle cite dans le livre
-
Cited at 36:55 as the basis for her objection to the official EMA / WHO / ANSM pregnancy recommendations.Sources qu'elle cite dans le livre
- 256 ScienceDirect (Elsevier; American Journal of Obstetrics & Gynecology) — February 2024 paper reporting spike protein in placental tissue of two women vaccinated days before delivery ⧉ archivé
- 101 Internet Archive — confidential Pfizer document (translated) obtained via FOIA showing LNP biodistribution to the ovaries of female rats ⧉ archivé
- 252 ClinicalTrials.gov — record NCT04754594, Pfizer/BioNTech BNT162b2 trial in pregnant women
- 253 ClinicalTrials.gov — protocol document (Prot_000.pdf) for NCT04754594, the Pfizer/BioNTech pregnancy trial
Pfizer : scandaleuses révélations sur l'essai clinique
-
Pierre describes this around 08:21 of the interview. The arrangement is a structural source of bias.Sources qu'elle cite dans le livre
- 150 OpenVAET (Substack) — "Pfizer/BioNTech C4591001 Trial Audit" article (Pierre/OpenVAET's reanalysis of the court-released trial database)
- 156 Society for Clinical Data Management (SCDM) — Audit Trail Review (ATR) Industry Position Paper, version PR1, April 2021 ⧉ archivé
- Pfizer C4591001 trial database / SAS XPT (transport) files (named in prose as the database to be requested, including local and central PCR results)
-
Cited throughout the interview (~26:53, ~42:25). Pierre publishes source code with each finding.Sources qu'elle cite dans le livre
- 85 DavidHealy.org — "Disappeared in Argentina" (account of Augusto Roux's case and the Argentinean Pfizer trial site)
- 86 VaccineHarm (WordPress) — "Augusto German Roux" post, dated 29 December 2020 (documentation of Roux's trial injuries)
- 88 PubMed (NCBI) — peer-reviewed article co-authored by Augusto Roux and Brianne Dressen (PMID 36710689) on confirmed vaccine-induced injuries
- Pfizer C4591001 court-released database — SAS XPT ("transport") files made public by court decision (CDISC-format datasets generated by Pfizer; PHMPT/FOIA release)
-
Cited at ~28:15. Independently cross-references Cotton's Process-2-substitution claim.Sources qu'elle cite dans le livre
- 297 European Medicines Agency (EMA) — press release "Cyberattack on EMA – update 5"
- 298 European Medicines Agency (EMA) — press release "Cyberattack on EMA – update 4"
- 299 European Medicines Agency (EMA) — Comirnaty EPAR Public Assessment Report (CHMP assessment, 19 February 2021)
- 300 The BMJ — rapid response (rr-2) to article bmj.o1731 by Joshua Guetzkow on the Process 1 vs Process 2 manufacturing-change issue ⧉ archivé
- 296 New England Journal of Medicine — C4591001 clinical study protocol (supplementary appendix to NEJMoa2034577, the December 2020 95%-efficacy publication) ⧉ archivé
-
Cited at ~53:47. The audit trail would resolve the 301-disappeared-subjects question definitively.Sources qu'elle cite dans le livre
Christine Cotton - Biostatisticienne - Lanceuse d'alerte
-
Cited at ~17:45 as the smoking-gun proof regulators knew about waning protection at the moment of authorization.Sources qu'elle cite dans le livre
- 134 Haute Autorité de Santé (HAS) — opinion/report on the COVID-19 vaccination strategy and the place of the mRNA vaccine Comirnaty (BNT162b2), December 2020 ⧉ archivé
- 135 Pfizer/FDA — BNT162b2 Module 1.6.3 Correspondence Regarding Meetings (released via PHMPT FOIA), Oct 2023 ⧉ archivé
- 130 FDA — 'Emergency Use Authorization for Vaccines to Prevent COVID-19; Guidance for Industry' (Immunogenicity criteria chapter) ⧉ archivé
- 131 Pfizer — Clinical report (Dec 10, 2020), Phase 1/2 immunogenicity results, neutralizing antibody geometric means, 18-55 years (FDA-hosted)
-
Referenced at ~20:39 / ~22:24 as the work that pushed her back to dissecting the Pfizer trial.Sources qu'elle cite dans le livre
- 37 FranceSoir — 'Les Débriefings' video: alert on VAERS data, 67% of registered deaths occur within 21 days (Cotton's August 2021 presentation of her VAERS analysis)
- 35 VAERS — Vaccine Adverse Event Reporting System (co-managed by CDC and FDA), public dataset
- 36 SAS Institute — SAS (Statistical Analysis System) software, health care page
- 38 Jonville-Béra (Head of French Pharmacovigilance Centers) — 2006 article on vaccine adverse events (PubMed)
-
Cited at ~39:51 as the legal mechanism by which the GCP critique could reverse liability from states to manufacturers.
-
Cited at ~40:50. Cotton confirms she kept the print-screens before LinkedIn shut her account.
REVAV AG Intervention de Christine Cotton Biostatisticienne octobre 2022
-
Cited at ~07:01 as the lone politician who let the cat out of the bag and then "disappeared" from media.Sources qu'elle cite dans le livre
- 133 France Info (francetvinfo.fr) — news article on Philippe Douste-Blazy's November 9, 2020 interview ('Vaccin contre le coronavirus: Philippe Douste-Blazy exhorte à la patience')
- 132 bioRxiv preprint (2020.09.08.280818) — Pfizer/BioNTech preclinical immunogenicity study of BNT162b2 in macaques ⧉ archivé
- 134 Haute Autorité de Santé (HAS) — December 2020 opinion on the COVID-19 vaccination strategy and the place of the mRNA vaccine Comirnaty (BNT162b2) ⧉ archivé
- 135 PHMPT (FDA-released Pfizer documents) — BNT162b2 Module 1.6.3 Correspondence Regarding Meetings (125742_S1_M1 meeting correspondence) ⧉ archivé
-
Anchors the strongest "nothing was learned in 22 months" argument in the interview.Sources qu'elle cite dans le livre
- 48 EMA — Comirnaty EPAR Risk Management Plan summary (archived 14 Feb 2021 via web.archive.org), the December 2020 / initial RMP listing anaphylaxis as an important identified risk and pregnancy/immunocompromised/comorbidities/autoimmune/interactions/long-term safety as missing information
- 63 EMA — Comirnaty EPAR Risk Management Plan summary (archived 5 Dec 2021 via web.archive.org), the updated RMP v2.3 (submitted 24 Sept 2021) adding myocarditis/pericarditis as a new important identified risk
-
Cited at ~25:21 as the methodological justification for the order-of-magnitude scaling argument.
[DEBRIEF] La biostatisticienne Christine Cotton sur l'efficacité du vaccin anti-COVID Pfizer
-
Cited at ~28:26 — institutional knowledge of severe allergic reactions before mass vaccination.Sources qu'elle cite dans le livre
- 49 CNBC news article (9 December 2020) — 'Pfizer jab warning for people with history of significant allergic reactions,' reporting the UK MHRA alert
- 47 Pfizer/BioNTech press release (14 December 2020) on the Pfizer.com newsroom
- 48 EMA — Comirnaty Risk Management Plan (RMP) summary, version dated 25 December 2020 (archived via web.archive.org)
-
Cited at ~21:34 as the methodological reason real-world studies systematically conclude there is no problem.
-
Cited at ~40:05 as evidence the accelerated-development model is being normalized.Sources qu'elle cite dans le livre
-
OPECST hearing referenced at ~03:07; Maddie de Garay omission detailed at ~17:48.Sources qu'elle cite dans le livre
- 76 FDA — Pfizer C4591001 clinical study report / safety data for 12-15 year olds (BNT162b2 adolescent trial), FDA media download
- 75 Siri & Glimstad LLP (Aaron Siri) — Letter to Federal Health Agencies Regarding Maddie [de Garay] and Clinical Trials for Children (October 2021)
- 271 Stephanie de Garay (@shdegaray73) — Twitter/X post dated December 3, 2022
Christine Cotton révèle le scandale des vaccins anticovid !
-
Cited at ~01:32 by Dupont-Aignan as the moment Pfizer publicly admitted the transmission gap.Sources qu'elle cite dans le livre
- 241 European Parliament — webstreaming of the Special Committee on the COVID-19 Pandemic (COVI) hearing, 10 October 2022 (the session at which Janine Small testified in place of Albert Bourla)
- 242 Tweet by MEP Rob Roos (X/Twitter), 11 October 2022, posting the clip in which Janine Small admits transmission was never studied in the trial
- 74 FDA — VRBPAC / briefing document for BNT162b2 emergency use authorization in adolescents 12-15 (April/May 2021)
-
Cotton states at ~04:35 that she has the full record. Worth requesting a sharable copy from her estate.Sources qu'elle cite dans le livre
- 85 David Healy (davidhealy.org) — "Disappeared in Argentina" article on Augusto Roux's case
- 86 VaccineHarm (WordPress blog) — "Augusto German Roux" post, 29 December 2020
- 87 YouTube video (Brianne Dressen testimony quoted in the book)
- 88 PubMed-indexed article co-authored by Augusto Roux and Brianne Dressen (PMID 36710689)
-
Referenced at ~04:35 alongside the Roux case.Sources qu'elle cite dans le livre
-
Maintenance: once external_links.html is the single source of truth, each interview brief should hyperlink in.Sources qu'elle cite dans le livre
- 241 European Parliament — webstreaming of the Special Committee on the COVID-19 Pandemic (COVI) hearing, 10 October 2022
- 243 Pfizer (cdn.pfizer.com) — C4591001 Clinical Protocol, November 2020 ⧉ archivé
- 134 Haute Autorité de Santé (HAS, has-sante.fr) — opinion on vaccination strategy and the place of the mRNA vaccine Comirnaty (BNT162b2), December 2020 ⧉ archivé
COVID : les vérités cachées de la politique vaccinale - Christine Cotton
-
Cited at ~04:59. The clearest direct admission from the Pfizer CEO.Sources qu'elle cite dans le livre
-
Cited at ~39:59 — Cotton testified in camera; the parliamentary follow-up is documented in the interview.Sources qu'elle cite dans le livre
- 200 Assemblée nationale (OPECST) — interim/draft report on COVID-19 vaccine adverse events ('rapport EI vaccins COVID'), published June 9, 2022
- 192 Assemblée nationale (OPECST) — information report 'The Covid-19 Vaccine Strategy' / 'La stratégie vaccinale contre la Covid-19,' dated December 15, 2020
-
Cited at ~19:49 — the AstraZeneca counterpart to the Pfizer trial-injury cases.Sources qu'elle cite dans le livre
- 87 YouTube — video of Brianne Dressen's testimony (her account of injury after AstraZeneca trial dose, including writing goodbye letters)
- 88 PubMed (NCBI) — article co-authored by Augusto Roux and Brianne Dressen on vaccine-induced injuries / clinical trial adverse events
- 234 YouTube — video of Brianne Dressen's hearing/testimony before US Senator Ron Johnson
Actualité de la semaine et invitée exceptionnelle, la biostatisticienne Christine COTTON
-
Cited at ~51:50 as the strongest pediatric-trial admission.Sources qu'elle cite dans le livre
- 76 FDA — Pfizer/BioNTech BNT162b2 clinical data for adolescents (12-15 yrs) / Maddie de Garay SAE narrative, FDA media document (April 2021)
- 74 FDA — Pfizer/BioNTech clinical report for adolescents aged 12-15 and young people under 25, FDA media document (released April 2021)
- 123 FDA — Pfizer/BioNTech COVID-19 vaccine pediatric (6 months-4 years / under-5) clinical data, FDA media document (2022)
- 115 FDA — Pfizer/BioNTech COVID-19 vaccine 5-11 years FDA briefing/clinical document presented to VRBPAC, FDA media document (26 October 2021)
- 116 FDA — Pfizer/BioNTech COVID-19 vaccine 5-11 years FDA briefing/clinical document presented to VRBPAC, FDA media document (26 October 2021)
- 117 FDA — Vaccines and Related Biological Products Advisory Committee (VRBPAC) October 26, 2021 meeting announcement
- 118 ClinicalTrials.gov — Pfizer/BioNTech pediatric trial C4591007 (NCT04816643), registry record
-
Cited at ~59:50 as undercutting the public-health rationale for the pass vaccinal.
-
Mentioned ~01:01:02 — useful for a future entry on official labels vs public messaging.Sources qu'elle cite dans le livre
- EMA — Comirnaty EPAR Summary of Product Characteristics / Product Information (current, undated version)
- EMA — Comirnaty EPAR Product Information / SmPC, archived version of 24 December 2020 (via Wayback Machine)
- 48 EMA — Pfizer Comirnaty Risk Management Plan (RMP) summary, 25 December 2020 (archived via Wayback Machine)
- 246 HAS (Haute Autorité de Santé) — Vaccination strategy: place of the mRNA vaccine Comirnaty (BNT162b2), opinion of December 2020 (modified February 2021) ⧉ archivé
- 247 UK Government (MHRA) — Summary Public Assessment Report for Pfizer/BioNTech COVID-19 vaccine, section 3.4 Toxicology ⧉ archivé
-
Cited at ~01:02:50 — Cotton presents the timing as a coincidence but flags it as troubling.
"La Commission veut prolonger ce pass sans base scientifique !" Virginie Joron, Christine Cotton
-
Cited at ~12:45 — Cotton's most concrete recomputation showing efficacy ~56% rather than 95%.Sources qu'elle cite dans le livre
- FDA — Pfizer/BioNTech BNT162b2 clinical report / VRBPAC efficacy results table (PCR-confirmed symptomatic COVID-19), 10 December 2020 (92-page report)
- Public Health and Medical Professionals for Transparency (PHMPT) — court-released Pfizer C4591001 documents and SAS/XPT datasets (FOIA litigation led by Aaron Siri) ⧉ archivé
- 150 OpenVAET (Substack) — 'Pfizer/BioNTech C4591001 Trial Audit'
-
Cited at ~28:05 — relevant to the wider OPECST hearings in Cotton's archive.Sources qu'elle cite dans le livre
- 200 OPECST (Office parlementaire d'évaluation des choix scientifiques et technologiques) — interim report on adverse events of COVID-19 vaccines, published 9 June 2022
- 192 OPECST / Assemblée nationale — information report 'The Covid-19 Vaccine Strategy' (La stratégie vaccinale contre la Covid-19), 15 December 2020
-
Cited at ~19:23 — central to Cotton's argument that the trial centers were not properly audited.Sources qu'elle cite dans le livre
- PHMPT — court-released Pfizer C4591001 SAS/XPT 'transport' datasets (CDISC-format clinical database), released following the FDA FOIA court decision (Aaron Siri) ⧉ archivé
- 87 YouTube — video relating to the Argentine site / Augusto Roux case
- 88 PubMed — peer-reviewed article (PMID 36710689) on the Pfizer C4591001 trial data integrity
- 85 DavidHealy.org — 'Disappeared in Argentina' (account of Augusto Roux's case at the Cosme Argerich Central Military Hospital)
- 86 VaccineHarm (WordPress) — 'Augusto German Roux', 29 December 2020
-
Cited at ~24:27 — Joron describes asking Commissioner Kyriakides why Valneva was paused while 4 bn mRNA doses were already stockpiled.
Autorisation du vaccin COVID : erreurs ou complicités ?
-
Anchors the strongest specific claim in the interview (~02:54): the 95% headline was confounded by symptom suppression.
-
Cited at ~13:48 as proof Brussels knew boosters would be required.Sources qu'elle cite dans le livre
- 237 Michele Rivasi (MEP) website — debrief/interview with Christine Cotton on the efficacy of the Pfizer anti-COVID vaccine (May 2022)
- 241 European Parliament multimedia webstreaming — Special Committee on the COVID-19 pandemic (COVI), hearing of 10 October 2022
- 289 European Parliament press room news (12 April 2022) — the Parliament's special committee on COVID-19 (COVI) begins its work
- 290 European Parliament multimedia webstreaming — COVI committee / Policy Department A workshop, 9 March 2023
- 291 L'Humanite (humanite.fr) — video report "Vaccins Pfizer: le scandale des SMS continue" on the von der Leyen–Bourla text messages
-
Cited at ~06:00 — proof that Pfizer was already preparing boosters at the moment of initial authorization.Sources qu'elle cite dans le livre
- 124 FDA media/159195 — VRBPAC briefing document for the Pfizer-BioNTech COVID-19 vaccine in children 6 months through 4 years of age (June 2022), section 6.2 Uncertainties related to benefits
- 136 FDA media/152161 — Pfizer-BioNTech submission/briefing for the COVID-19 vaccine booster (third) dose to the FDA (September 2021)
- 137 Drugs.com / MedNews press release — "Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster" (September 2021); named in prose, no URL given
-
Cited at ~17:32 as evidence of the influence network around the Commission's vaccine strategy.
-
Cited at ~17:32 as exhibit A in the McKinsey-EU-pharma triangle.Sources qu'elle cite dans le livre
CeNC - Commission d'enquête nationale citoyenne - bio-statisticienne Christine Cotton témoigne
-
Cited at ~09:43 — supports the case-detection bias core argument.Sources qu'elle cite dans le livre
-
Referenced at ~09:43 — important provenance for any reader following the data.Sources qu'elle cite dans le livre
- Public Health and Medical Professionals for Transparency (PHMPT) — phmpt.org, the site posting the FDA's court-ordered released C4591001 clinical-trial documents ⧉ archivé
- 79 Complaint, PHMPT/de Garay v. FDA, filed 2022-10-11 (hosted on phmpt.org) — the litigation seeking the de Garay family's trial records ⧉ archivé
- 75 Siri & Glimstad LLP (Aaron Siri) — "Letter to Federal Health Agencies Regarding Maddie and Clinical Trials for Children", Oct 2021
-
The available video transcript ends abruptly around 13:23; the full hearing likely runs longer.
Les essais cliniques de Pfizer sont-ils frauduleux ? Avec Christine Cotton
-
Cited at ~07:41 — the central document supporting Cotton's "they vaccinated populations they hadn't tested" argument.Sources qu'elle cite dans le livre
- 48 EMA - Comirnaty (Pfizer/BioNTech) Risk Management Plan summary (RMP), version dated 25 December 2020 (archived via Wayback Machine, captured 14 Feb 2021)
- 245 EMA - Comirnaty (Pfizer/BioNTech) Risk Management Plan summary (RMP), version dated 25 December 2020 (archived via Wayback Machine, captured 14 Feb 2021)
- 243 Pfizer - C4591001 Clinical Protocol, November 2020 (BNT162b2 Phase 1/2/3 study protocol) ⧉ archivé
- 244 FDA - draft guidance 'Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials - Guidance for Industry'
-
Cited at ~15:12 — exemplifies Cotton's call for an independent multi-center audit.Sources qu'elle cite dans le livre
- 153 The BMJ (British Medical Journal) - Paul D. Thacker, 'Covid-19: Researcher blew the whistle on data integrity issues in Pfizer's vaccine trial' (BMJ 2021;375:n2635), published 2 November 2021 ⧉ archivé
- 152 Ventavia Research Group - corporate website ⧉ archivé
- 151 Twitter/X account of Dr. Lt. Col. Theresa Long (@ltctheresalong)
- 272 iambrookjackson.com - Brook Jackson case documents page (litigation document repository for U.S. ex rel. Jackson v. Ventavia/Pfizer)
-
Cited at ~17:31 — co-signatory of the report submitted to ANSM.Sources qu'elle cite dans le livre
-
Mentioned at the very end of the interview (~17:31).
Documents déclassifiés de Pfizer et revelations choc de Christine Cotton
-
Cited at ~09:33 — the most concrete cross-checkable data-integrity finding.Sources qu'elle cite dans le livre
- 85 DavidHealy.org blog — "Disappeared in Argentina" (account of Augusto Roux, the Argentine C4591001 trial participant whose serious adverse event was reclassified in the database)
- 86 VaccineHarm (WordPress) — "Augusto German Roux" post, 29 Dec 2020 (Roux's public disclosure of his medical documents from the Argentine Pfizer trial site)
- 88 PubMed (NCBI) — peer-reviewed article co-authored by Augusto Roux and Brianne Dressen documenting that four doctors confirmed his injuries were vaccine-induced (PMID 36710689)
-
Cited at ~06:30 — concrete proof of incomplete data handling at a known problematic center.
-
Cited at ~14:34 as a real legal consequence of the adverse-event data.
-
Cited at ~04:15 as the comparator that the COVID trials departed from.